Istiratumab

Drug Profile

Istiratumab

Alternative Names: MM-141

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adimab
  • Developer Adimab; Merrimack Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I Solid tumours
  • Preclinical Ovarian cancer

Most Recent Events

  • 31 Aug 2017 Merrimack Pharmaceuticals terminates a phase I trial due to sponsor decision in Solid tumours (Late-stage disease, Combination therapy) in USA (Parenteral) (NCT02538627)
  • 09 Aug 2017 Merrimack completes enrolment in the phase II CARRIE trial in Pancreatic cancer
  • 19 Jun 2017 Merrimack Pharmaceuticals completes enrolment in the phase II CARRIE trial for Pancreatic cancer (Combination therapy, Metastatic disease, First-line therapy) in USA, Spain, Canada, Germany, Poland and United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top